Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.
With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...
The next generation sequencing market offers significant opportunities by enhancing the diagnosis and treatment of chronic ...
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
How does personalised medicine work across different cancer types? Oncologist Dr Valerie Yang from OncoCare Cancer Centre ...
MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can ...
News-Medical.Net on MSN
Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations
Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its ...
Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...
The bank’s ‘Today, Tomorrow, Forever’ framework helps families organise and navigate their wealth across three interconnected ...
Expanded newborn genetic screening can diagnose hundreds of actionable conditions, allowing for earlier treatment.
In a new paper presented at IEDM 2025, imec reports on the successful fabrication of highly uniform nanopores with diameters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback